Clinical Candidate VT-1161's Antiparasitic Effect In Vitro, Activity in a Murine Model of Chagas Disease, and Structural Characterization in Complex with the Target Enzyme CYP51 from Trypanosoma cruzi

A novel antifungal drug candidate, the 1-tetrazole-based agent VT-1161 [(R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)-1-{5-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin-2-yl}propan-2-ol], which is currently in two phase 2b antifungal clinical trials, was found to be a tight-binding ligand...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Antimicrob Agents Chemother
Κύριοι συγγραφείς: Hoekstra, William J., Hargrove, Tatiana Y., Wawrzak, Zdzislaw, da Gama Jaen Batista, Denise, da Silva, Cristiane F., Nefertiti, Aline S. G., Rachakonda, Girish, Schotzinger, Robert J., Villalta, Fernando, Soeiro, Maria de Nazaré C., Lepesheva, Galina I.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Society for Microbiology 2016
Θέματα:
Experimental Therapeutics
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4750653/
https://ncbi.nlm.nih.gov/pubmed/26643331
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02287-15
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια